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Abstract This randomized, placebo-controlled, evaluator-blind, five-waycrossover studycompared the equivalence
intermsof FEV1response to single ascendingcumulative doses of salbutamol (100--400 mg) fromAirmax
TM, a newmulti-
dose drypowder inhaler, in comparisonwithplacebo, the same dose froma standardpressurizedmetered dose inhaler
(Ventolins) or atdouble the dose fromthe drypowder inhalers Diskhalers and Accuhalers. Sixty-one adult asthmatic
subjectswith FEV150--80%predictedandX15% increasein FEV1to salbutamoltookpart.Equivalencewasdeclaredifthe
95%CIfor theratio ofthe FEV1responses tothetwotreatmentswaswithintherange 90--111%.Following the cumulative
four doses, FEV1 (l) changes pre-dose to the highest dose were: 2.53--3.31, 2.47--3.30, 2.51--3.35, 2.52--3.31and 2.57--2.55
for AirmaxTM salbutamol, salbutamol Ventolins, salbutamol Diskhalers, salbutamol Accuhalers and placebo, respec-
tively.The 95% CIs for the ratio of AirmaxTM salbutamolto each ofthe active deviceswerewithin75% demonstratinga
1:1dose equivalencebetween AirmaxTM salbutamol and Ventolins and a1:2 dose equivalencebetweeneachofthe other
two salbutamol dry powder devices. Adverse events profiles were similar for all treatments. In conclusion, the novel
multidose inhaler AirmaxTM salbutamol is as efficacious and safe as the pressurized metered dose inhaler without the
need for co-ordinating actuation and inhalation and with the added benefit of a dose counter.r 2002 Published by Elsevier
Science Ltd
doi:10.1053/rmed.2002.1360, available online at http://www.idealibrary.comon
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Salbutamol, a potent and selective b2-agonist with a ra-
pid onset of action, has traditionally been administered
by pressurized metered dose inhaler (pMDI). Such de-
vices have the disadvantage of requiring co-ordination
of actuationwith inspiration resulting in sub-optimal de-
livery for many patients (1) and their use is not recom-
mended in children (2). With the added factor of the
phasing out of the use of chloro£uorocarbon propel-
lants, dry powder inhalers (DPIs), which require neither
propellant nor actuation^inhalation co-ordination, have
gained widespread and increasing acceptance. However,Received 20 December 2001, accepted in revised form13 February
2002.
Correspondence should be addressed to: Michae« l G.L.Hertog, PhD,
Medical A¡airs,Yamanouchi Europe BV, Elisabethhof19, 2350 AC
Leiderdorp,The Netherlands.Fax: +31715455739;
E-mail: mhertog.nl@yamanouchi-eu.commost DPIs rely upon the patient’s vigorous inspiratory
e¡ort to both disperse and deliver the powder formula-
tion. This has the potential consequence that patients
with low inspiratory £ow rates such as young children,
the elderly, or patients undergoing a severe exacerbation
of asthma might not gain optimum therapeutic
bene¢t (3).
AirmaxTM (Yamanouchi, Leiderdorp, The Nether-
lands) is aYamanouchi Europe trademark for a newmul-
tidose dry powder inhaler (up to 200 doses) which
utilizes proprietary technology known as the X-ACTTM
systemFActive-metering, Cyclone-separator Technol-
ogy (Fig.1).This system has been shown to provide accu-
rate and consistent dosing (4) and good lung deposition
with a high ¢ne particle fraction even at low inspiratory
£ow rates (5).
AirmaxTM employs a lactose blend and air-pressure
from an internal pump to activelymeter amore accurate
and consistent dose to the patient than pure drug
FIG. 1. Diagramof Airmax inhaler with XACTTM.
494 RESPIRATORYMEDICINEgravity-driven devices (4).The patient’s inspired air is en-
trained in a cyclone, where precision-manufactured
ramps on theroof delayemissionuntil theblend ismicro-
nized.This produces a very high ¢ne particle fraction of
drug to the lungs, largely independent of the patient’s in-
spiratory e¡ort (5). The inhaler is simply operated by
opening of the mouthpiece, inhaling and closing the
mouthpiece.Closing of themouthpiece triggers the pre-
cise dose counter.
In order to assess the potential bene¢t of using
this inhaler for the delivery of salbutamol, the
bronchodilator response and safety were examined in
adults with asthma. Response was compared to an
equivalent dose from a pMDI (Ventolins) and also to
twice the dose from two widely used DPI devices,
Diskhalers and Accuhalers, all three from Glaxo
SmithKline.METHODS
This was a randomized, placebo-controlled, evaluator-
blind, dose-ranging, ¢ve treatment, ¢ve period, cross-
over study. The study was conducted in two clinical re-
search centers one in George and one in Bloemfontein,
both Republic of South Africa. Adult asthmatic subjects
of either sex, with FEV1 50^80% predicted for age,
height and gender were enrolled, provided that they
were otherwise healthy and had stable asthmatic dis-
ease. Each subject had to demonstrate prior reversible
bronchoconstriction of a X15% increase in FEV1 within
30min of a 200mg dose of salbutamol from a pMDI. All
were concurrently taking only short-acting inhaled b2-
agonist therapy for asthma. Patients were excluded if
they had had a respiratory tract infection or sinusitis
within the previous 6 weeks.Other exclusion criteria in-
TABLE 1. Demographic characteristics (mean7SD) of 61
patients (PP)
Gender (FM) 35/26
Race (Caucasian/non-caucasian) 49/12
Age (year) 29.479.5
Range 18^61
Height (cm) 170710
Range 1.43^1.90
Weight (kg) 72.7715.1
Range 44^107
FEV1 (l) (%predicted) 2.4770.59
Range 1.09 3^.69
PEF (l/min) 382783
Range 204 5^68
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costeroids, oral theophyllines, oral or long-acting b2-
agonists and anti-cholinergics. Following screening as-
sessments, subjects attended the clinic for ¢ve treat-
ment periods, 4 7^ days apart, for receipt of each
treatment as single doses in an ascending cumulative
fashion at 30min intervals. For AirmaxTM and pMDI, the
doses of salbutamol given were 100mg followed by 100,
200 and 400mg, i.e. a total dose of 800mg over a period
of 90min. For Diskhalers and Accuhalers, the doses
were 200, 400 and 800mg, a total dose of 1600mg. At
each visit, FEV1 and PEF were measured for 30min and
immediately before each dose of test treatment and
again at 2, 5, 10, 15 and 30min following each dose. For
each time point, the highest of three lung functionmea-
surements was taken.Vital signs (blood pressure, heart
rate and ECG) were recorded before and 15 and 30min
post-dose. Blood samples for serum potassium and glu-
cose estimations were taken at 5min before and 25min
after dosing. Any adverse events occurring during the
study were fully documented. The study protocol was
approved by the local ethics committees of the centers
concerned and all patients gave written informed con-
sent for participation.
The primary e⁄cacy variable was the mean FEV1 re-
sponse at each dose level, de¢ned as the average of the
two pre-dose determinations subtracted from the max-
imum FEV1 determination observed between 0 and
30min post-dose. Secondary outcomevariables included
the PEF response at each dose level, de¢ned as the max-
imum PEF determination observed between 0 and
30min post-dose. The primary study objective was to
evaluate the therapeutic equivalencebetweenAirmaxTM
salbutamol and salbutamol pMDI. Equivalence was de-
clared at a givendose level if the 95%CI for the di¡erence
between treatments was contained within 90 1^11%.
Comparisons were made also using PEF at each dose le-
vel.Further comparisonsweremade, using similar criter-
ia for equivalence, between AirmaxTM salbutamol and
double the dose of salbutamol from each of the other
two MDPI devices, Diskhalers and Accuhalers. Air-
maxTM salbutamol was also compared with placebo in
order to establish that salbutamol from the new inhaler
was an e¡ective treatment. All comparisons were made
using data from only those subjects who completed the
study according to the protocol (Per-Protocol Popula-
tion PP).
RESULTS
Sixty-¢ve patients were randomized to treatment. The
PP population comprised 61 patients, of whom 26 were
male.Demographic details are listed inTable1.Meanper-
centpredictedpre-bronchodilator FEV1was 67.9%. After
AirmaxTM salbutamol and salbutamol Ventolins meanFEV1 increased incrementally with successive doses for
both treatments in a similar manner. The ratio of FEV1
responses for the two devices was contained within the
95% CI 90 1^11% for each dose level, being within 5% of
each other (Table 2). Thus, the two treatments were
shown to be therapeutically equivalent.Comparisons of
FEV1responses for Airmax
TM salbutamol at each dose le-
velwith double the dose level for salbutamol Diskhalers
and Accuhalers (Table 2) showed that the 95% CIs for
the ratio of AirmaxTM salbutamol to each of the other
DPI devices were also within 5%, demonstrating that a
dose from AirmaxTM salbutamol is equivalent to twice
that from Diskhalers and Accuhalers. The 95%CI for
the ratio of response of AirmaxTM salbutamol compared
to placebowas at least13% greater at the100mg dose le-
vel and at least 26% greater at the 400mg dose level
(Table 2).The di¡erences between AirmaxTM salbutamol
and placebo were signi¢cant (Po0.05) at all dose
levels.
Results were similar for mean PEF, which also in-
creased incrementally with each dose level (Fig.2) and
for which the 95% CIs of the treatment di¡erences be-
tween all of the active devices at each dose were within
4% of each other.
SAFETY
Themajority of adverse events seen during the study on
active treatment were typical of salbutamol treatment
and included headache, tachycardia, dizziness and tre-
mor (Table 3). There were no signi¢cant di¡erences be-
tween treatments and there were no serious adverse
events. Three patients withdrew from the study due to
adverse events (one patient with exacerbation of asth-
ma, two with hayfever) that were not considered attri-
butable to study drug. The mean value for potassium
was statistically signi¢cantly lower after treatment with
salbutamol Diskhalers (3.83mmol/l) than after Air-
TABLE 2. Comparison ofmaximum FEV1response (l) ateach dose level for Airmax
TM salbutamol, salbutamol Diskhalers, salbutamol Accuhalers andplacebo (PP)
AirmaxTM SalbutamolpMDIVentolins Salbutamol Diskhalers Salbutamol Accuhalers Placebo
Doses (mg)a FEV1 (l) FEV1 (l) Estimate
b of %
ratio (95% Cl)
AirmaxTM:
Ventolins
pMDI
FEV1 (l) Estimate
b of %
ratio (95% Cl)
AirmaxTM:
Diskhalers
FEV1 (l) Estimate
b of %
ratio (95% Cl)
AirmaxTM:
Accuhalers
FEV1 (l) Estimate
b of %
ratio (95% Cl)
AirmaxTM:
placebo
Pre-dose 2.53 2.47 F 2.51 F 2.52 F 2.54 
100/200 3.01 2.95 101.9 (99.4,104.4) 3.04 98.9 (96.4,101.4) 2.96 101.5 (99.0,104.0) 2.57 116.7 (113.8,119.6)
100/200c 3.12 3.10 100.8 (98.6,103.1) 3.17 98.3 (96.1,100.5) 3.09 101.0 (98.8,103.3) 2.58 121.1 (118.4,123.8)
200/400 3.21 3.21 100.0 (97.7,102.4) 3.26 98.4 (96.1,100.7) 3.21 100.1 (97.8,102.5) 2.54 126.4 (123.4,129.4)
400/800 3.31 3.30 100.3 (97.9,102.8) 3.35 99.0 (96.5,101.4) 3.31 100.2 (97.8,102.7) 2.55 130.0 (126.7,133.3)
aAirmaxTM/Diskhalersor Accuhalers.
bLeast squaremeans estimate.
cSecond.
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FIG. 2. Meanchange in PEFafter inhalationof salbutamol from
AirmaxTM (100 mg/dose), pMDI (100 mg/dose), Diskhalers
(200 m/dose),Accuhalers (200 m/dose) andplacebo (PP).
BRONCHODILATINGEFFECTSOFSALBUTAMOLFROMAIRMAX 497maxTM salbutamol (3.60mmol/l).Therewere a total of 24
patients with out-of-range glucose values at some time
during the study.However, therewas no statistically sig-
ni¢cant di¡erence in glucose values between either ac-
tive treatment with the exception of a higher value
(4.94mmol/l) with AirmaxTM than with Ventolin
(4.69mmol/l).None of the di¡erences in either heartrate
(not shown), ECG (not shown), potassium or glucose va-
lues were considered clinically relevant.
DISCUSSION
This study shows that the short-acting b2-agonist salbu-
tamol deliveredby a novel inhaler AirmaxTM is therapeu-
tically equivalent on a dose-for-dose basis to salbutamol
from a pMDI (Ventolin) in adult asthmatic patients.
A number of previouslypublished studies have demon-
strated a better response with salbutamol pMDI than
with inhalation powder (6 9^). Although earlier work
suggested that DPIs deliver only half as e⁄ciently as
pMDIs (10 1^3) and this forms thebasis ofmostof the cur-
rent clinical practices (14), more recent studies have
shown that drug delivery from e⁄cient DPI systems has
beenunderestimated.Traditional advicehasbeen to dou-TABLE 3. Adverse events reportedby 5% ormore patients by
Run-in Salbutamol
AirmaxTM
Ventolins
^MDI
N % N % N %
Chesttightness 0 (0) 0 (0) 0 (0)
Headache 0 (0) 8 (12) 3 (5)
Tachycardia 1 (2) 2 (3) 1 (2)
Dizziness 1 (2) 2 (3) 3 (5)
Tremor 0 (0) 8 (12) 2 (3)
Sinusitis 0 (0) 0 (0) 1 (2)ble the dose of salbutamol if delivered from a DPI over
that from apMDI.However, in vitro studieshave indicated
a respirable fraction from AirmaxTM that is comparable
to that from a pMDI, and for this reason the doses cho-
sen in the comparative study were the same in both Air-
maxTM and pMDI and half that used in Diskhalers and
Accuhalers (15).
There have been a number of di¡ering guidelines as to
what studies should be performed and what constitutes
bioequivalence between two di¡erent inhaled broncho-
dilators. A consensus statement (16) has recommended
that whilst in vitro studies can be useful in determining
lung deposition and particle size distribution, evaluation
of therapeutic assessment is the preferredmethod.The
con¢dence interval (CI) approach, ¢rst introduced in
1987 (17), has been used in a number of comparisons of
newMDPIs with pMDIs withwidely di¡ering limits with-
inwhich equivalencewas declared.These have included a
90%CI of a ratio between 80 and 120% (18), mean FEV1
within 7 0.25 l (19) and those recommended by the
Food and Drug Administration, (FDA), which considers
that two inhaled formulations are bioequivalent if
the 90%CI of the relative potency is between 0.67 and
1.50 (20).
In the present study, the 95%CI interval within which
equivalence was deemed to have been established was
90 1^11%.Asrecommendedin studies designed to demon-
strate bioequivalence, results were based on the PP po-
pulation.The asthma of the patients enrolledwas stable,
enabling accurate and repeatable measurements of
bronchodilatation and the robustness of the data was
further supportedby the signi¢cantdi¡erences frompla-
cebo for each of the active devices.The results show that
at each dose level, the di¡erences between the treat-
ments are within 7 5%, demonstrating clear equiva-
lence. It was further shown that the di¡erences
between AirmaxTM salbutamol and the estabished
MDPIs (Ventolins Accuhalers and Ventolins Diskha-
lers) are within 7 4%, con¢rming therapeutic equiva-
lence to these devices. In common with other powder
devices, the Accuhaler and Diskhaler required twice the
dose of salbutamol compared to a pMDI to produce antreatmentperiod
Salbutamol
Diskhalers
Salbutamol
Accuhalers
Placebo Overall
N % N % N % N %
0 (0) 1 (2) 15 (23) 16 (25)
11 (17) 4 (6) 7 (11) 24 (37)
6 (9) 2 (3) 1 (2) 8 (12)
2 (3) 1 (2) 1 (2) 8 (12)
13 (20) 4 (6) 0 (0) 15 (23)
0 (0) 1 (2) 3 (5) 4 (6)
498 RESPIRATORYMEDICINEequivalent therapeutic e¡ect. For the ¢rst time, an
MDPI has been shown to deliver a therapeutic dose of
salbutamol equivalent to the same dose delivered by a
conventional pMDI.
The safety and tolerabilityofAirmaxTM salbutamolhas
been demonstratedby a similar low incidence of adverse
e¡ects in all treatment groups, many events being di-
rectly attributable to the knownpharmacological pro¢le
of salbutamol, particularly at high doses.There were no
clinically important di¡erences between the salbutamol
inhalers in heart rate, ECG parameters, serum glucose
or serum potassium. No values of clinical concern were
observed in any of the safety evaluations carried out in
this study.
It is concluded that AirmaxTM salbutamol is a safe and
convenient alternative for administering salbutamol in
asthmatic patients. AirmaxTM eliminates the need for
co-ordination of actuation and inhalation typical for con-
ventional pMDIs, it is equippedwith a precise dose coun-
ter allowing dose monitoring and it is as e⁄cacious and
well tolerated as other dry powder inhalers at only half
the dose.
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